Skin And Skin Structure Infections (SSSI) – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：94頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Skin And Skin Structure Infections (SSSI) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2012', provides an overview of the Skin And Skin Structure Infections (SSSI) therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI). 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI).
- A review of the Skin And Skin Structure Infections (SSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin And Skin Structure Infections (SSSI) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) pipeline depth and focus of Skin And Skin Structure Infections (SSSI) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2012', provides an overview of the Skin And Skin Structure Infections (SSSI) therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI). 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI).
- A review of the Skin And Skin Structure Infections (SSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Skin And Skin Structure Infections (SSSI) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) pipeline depth and focus of Skin And Skin Structure Infections (SSSI) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Skin And Skin Structure Infections (SSSI) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Skin And Skin Structure Infections (SSSI) 8
Skin And Skin Structure Infections (SSSI) Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Skin And Skin Structure Infections (SSSI) Therapeutics – Products under Development by Companies 15
Companies Involved in Skin And Skin Structure Infections (SSSI) Therapeutics Development 17
GlaxoSmithKline plc 17
Takeda Pharmaceutical Company Limited 18
Rib-X Pharmaceuticals, Inc. 19
Paratek Pharmaceuticals, Inc. 20
Affinium Pharmaceuticals, Inc. 21
Basilea Pharmaceutica Ltd. 22
CrystalGenomics, Inc. 23
PolyMedix, Inc. 24
Nabriva Therapeutics AG 25
Cempra Pharmaceuticals, Inc. 26
Trius Therapeutics, Inc. 27
Skin And Skin Structure Infections (SSSI) – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
GSK1322322 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AFN-1252 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TAK-599 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TAK-599 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Omadacycline - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PMX-30063 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BC-3781 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BC-7013 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RX-3341 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RX-1741 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CG400549 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Oritavancin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CEM-102 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Tedizolid Phosphate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Tedizolid Phosphate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
JNJ-Q2 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ABI-0043 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Ceftobiprole Medocaril - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Skin And Skin Structure Infections (SSSI) Therapeutics – Drug Profile Updates 67
Skin And Skin Structure Infections (SSSI) Therapeutics – Discontinued Products 84
Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 85
Skin And Skin Structure Infections (SSSI) – Product Development Milestones 86
Featured News & Press Releases 86
Aug 21, 2012: PolyMedix Announces Presentation Of Antibiotic Studies At ICAAC 86
Aug 07, 2012: Affinium Pharma Completes Recruitment For Phase II Clinical Trial Of AFN-1252 In Acute Bacterial Skin & Skin Structure Infections 86
Jun 12, 2012: PolyMedix Receives USAN Approval For Generic Name Of Brilacidin For PMX-30063 87
Apr 23, 2012: PolyMedix Announces Positive Results From Phase II Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic 88
Apr 02, 2012: Trius's Antibiotic Tedizolid Demonstrates High Efficacy In Patients With Cellulitis 89
Feb 16, 2012: Trius Announces Issuance Of Tedizolid Patent In China 90
Feb 09, 2012: Cubist Receives CUBICIN Paragraph IV Notice Letter 90
Feb 01, 2012: Affinium Announces First Patient Dosed With Oral AFN-1252 In Phase II Clinical Trial For Acute Bacterial Skin & Skin Structure Infections 91
Jan 23, 2012: Trius Earns $5m Milestone Payment From Bayer For Successful Completion Of First Phase III Trial Of Tedizolid 92
Dec 19, 2011: Trius Reports Positive Results From First Phase III Trial Of Tedizolid In Acute Bacterial Skin And Skin Structure Infections 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94
List of Tables
Number of Products Under Development for Skin And Skin Structure Infections (SSSI), H2 2012 8
Products under Development for Skin And Skin Structure Infections (SSSI) – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Development by Companies, H2 2012 (Contd..1) 16
GlaxoSmithKline plc, H2 2012 17
Takeda Pharmaceutical Company Limited, H2 2012 18
Rib-X Pharmaceuticals, Inc., H2 2012 19
Paratek Pharmaceuticals, Inc., H2 2012 20
Affinium Pharmaceuticals, Inc., H2 2012 21
Basilea Pharmaceutica Ltd., H2 2012 22
CrystalGenomics, Inc., H2 2012 23
PolyMedix, Inc., H2 2012 24
Nabriva Therapeutics AG, H2 2012 25
Cempra Pharmaceuticals, Inc., H2 2012 26
Trius Therapeutics, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Skin And Skin Structure Infections (SSSI) Therapeutics – Drug Profile Updates 67
Skin And Skin Structure Infections (SSSI) Therapeutics – Discontinued Products 84
Skin And Skin Structure Infections (SSSI) Therapeutics – Dormant Products 85
List of Figures
Number of Products under Development for Skin And Skin Structure Infections (SSSI), H2 2012 8
Products under Development for Skin And Skin Structure Infections (SSSI) – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Skin And Skin Structure Infections (SSSI) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Skin And Skin Structure Infections (SSSI) 8
Skin And Skin Structure Infections (SSSI) Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Skin And Skin Structure Infections (SSSI) Therapeutics – Products under Development by Companies 15
Companies Involved in Skin And Skin Structure Infections (SSSI) Therapeutics Development 17
GlaxoSmithKline plc 17
Takeda Pharmaceutical Company Limited 18
Rib-X Pharmaceuticals, Inc. 19
Paratek Pharmaceuticals, Inc. 20
Affinium Pharmaceuticals, Inc. 21
Basilea Pharmaceutica Ltd. 22
CrystalGenomics, Inc. 23
PolyMedix, Inc. 24
Nabriva Therapeutics AG 25
Cempra Pharmaceuticals, Inc. 26
Trius Therapeutics, Inc. 27
Skin And Skin Structure Infections (SSSI) – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
GSK1322322 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AFN-1252 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TAK-599 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TAK-599 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Omadacycline - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PMX-30063 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BC-3781 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BC-7013 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RX-3341 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RX-1741 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CG400549 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Oritavancin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CEM-102 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Tedizolid Phosphate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Tedizolid Phosphate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
JNJ-Q2 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ABI-0043 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Ceftobiprole Medocaril - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Skin And Skin Structure Infections (SSSI) Therapeutics – Drug Profile Updates 67
Skin And Skin Structure Infections (SSSI) Therapeutics – Discontinued Products 84
Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 85
Skin And Skin Structure Infections (SSSI) – Product Development Milestones 86
Featured News & Press Releases 86
Aug 21, 2012: PolyMedix Announces Presentation Of Antibiotic Studies At ICAAC 86
Aug 07, 2012: Affinium Pharma Completes Recruitment For Phase II Clinical Trial Of AFN-1252 In Acute Bacterial Skin & Skin Structure Infections 86
Jun 12, 2012: PolyMedix Receives USAN Approval For Generic Name Of Brilacidin For PMX-30063 87
Apr 23, 2012: PolyMedix Announces Positive Results From Phase II Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic 88
Apr 02, 2012: Trius's Antibiotic Tedizolid Demonstrates High Efficacy In Patients With Cellulitis 89
Feb 16, 2012: Trius Announces Issuance Of Tedizolid Patent In China 90
Feb 09, 2012: Cubist Receives CUBICIN Paragraph IV Notice Letter 90
Feb 01, 2012: Affinium Announces First Patient Dosed With Oral AFN-1252 In Phase II Clinical Trial For Acute Bacterial Skin & Skin Structure Infections 91
Jan 23, 2012: Trius Earns $5m Milestone Payment From Bayer For Successful Completion Of First Phase III Trial Of Tedizolid 92
Dec 19, 2011: Trius Reports Positive Results From First Phase III Trial Of Tedizolid In Acute Bacterial Skin And Skin Structure Infections 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94
List of Tables
Number of Products Under Development for Skin And Skin Structure Infections (SSSI), H2 2012 8
Products under Development for Skin And Skin Structure Infections (SSSI) – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Development by Companies, H2 2012 (Contd..1) 16
GlaxoSmithKline plc, H2 2012 17
Takeda Pharmaceutical Company Limited, H2 2012 18
Rib-X Pharmaceuticals, Inc., H2 2012 19
Paratek Pharmaceuticals, Inc., H2 2012 20
Affinium Pharmaceuticals, Inc., H2 2012 21
Basilea Pharmaceutica Ltd., H2 2012 22
CrystalGenomics, Inc., H2 2012 23
PolyMedix, Inc., H2 2012 24
Nabriva Therapeutics AG, H2 2012 25
Cempra Pharmaceuticals, Inc., H2 2012 26
Trius Therapeutics, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Skin And Skin Structure Infections (SSSI) Therapeutics – Drug Profile Updates 67
Skin And Skin Structure Infections (SSSI) Therapeutics – Discontinued Products 84
Skin And Skin Structure Infections (SSSI) Therapeutics – Dormant Products 85
List of Figures
Number of Products under Development for Skin And Skin Structure Infections (SSSI), H2 2012 8
Products under Development for Skin And Skin Structure Infections (SSSI) – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32
